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targeted delivery of lysosomal 
enzymes to the endocytic 
compartment in human cells using 
engineered extracellular vesicles
Mai Anh Do1,3, Daniel Levy1,3, Annie Brown1, Gerard Marriott2 & Biao Lu1*
targeted delivery of lysosomal enzymes to the endocytic compartment of human cells represents 
a transformative technology for treating a large family of lysosomal storage diseases (LSDs). 
Gaucher disease is one of the most common types of LSDs caused by mutations to the lysosomal 
β-glucocerebrosidase (GBA). Here, we describe a genetic strategy to produce engineered exosomes 
loaded with GBA in two different spatial configurations for targeted delivery to the endocytic 
compartment of recipient cells. By fusing human GBA to an exosome-anchoring protein: vesicular 
stomatitis virus glycoprotein (VSVG), we demonstrate that the chimeric proteins were successfully 
integrated into exosomes which were secreted as extracellular vesicles (EVs) by producer cells. Isolation 
and molecular characterization of EVs confirmed that the fusion proteins were loaded onto exosomes 
without altering their surface markers, particle size or distribution. Further, enzyme-loaded exosomes/
EVs added to cultured medium were taken up by recipient cells. Further, the endocytosed exosomes/
EVs targeted to endocytic compartments exhibited a significant increase in GBA activity. Together, 
we have developed a novel method for targeting and delivery of lysosomal enzymes to their natural 
location: the endocytic compartment of recipient cells. Since exosomes/EVs have an intrinsic ability 
to cross the blood-brain-barrier, our technology may provide a new approach to treat severe types of 
LSDs, including Gaucher disease with neurological complications.
Lysosomal storage diseases (LSDs) are a group of over 50 inherited metabolic disorders that have a devastating 
effect and impose a heavy burden on both the patient and the health care system1–3. Although many of these dis-
orders are rare, the combined incidence is high with an estimation of 1 in 7,000~8,000 live births4. LSDs are het-
erogeneous; each one is caused by a defect to a different lysosomal enzyme. The loss of these enzymatic activities 
leads to accumulation of undegraded substrates, which can be toxic to cells and result in multiple organ damage5. 
The clinical signs and symptoms include facial dimorphism, hepatosplenomegaly, ocular impairment, skeletal 
and cardiovascular involvement, as well as hematological abnormalities. Moreover, two-thirds of patients with 
LSDs manifest distinct neurological symptoms, ranging from progressive neurodegeneration to severe cognitive 
impairment as well as epilepsies, behavioral abnormalities and/or psychiatric disorders6.
Current options for treating hereditary LSDs are limited. They include specific enzyme replacement therapy 
(ERT) with recombinant human enzymes or a handful of supportive measures7–9. ERT was first used to replace 
defective enzymes for Gaucher’s patients in the 1990s10,11. Subsequently, this approach became the standard of care 
and has extended to other LSDs including Fabry disease, Pompe disease, mucopolysaccharidosis, metachromatic 
leukodystrophy, and acid lipase deficiency12–16. Although ERT is effective in reversing the visceral and hemato-
logic manifestations associated with the mild form of the disease, critical limitations have emerged, including 
insufficient reversal of the pathology in tissues such as muscle, bone, cartilage, heart and lung17. Importantly, 
ERT has little effect on cases with severe neurological complications, putatively due to difficulty crossing the 
blood-brain barrier8,18. Although there are some promising outcomes recently to increase enzyme delivery to 
the brain, these methods tend to be more invasive and require additional improvements19,20. One solution to the 
current drawbacks of protein therapy to Gaucher treatment is to develop delivery systems that can both reach 
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and penetrate barriered tissues, such as the brain. Ideally, these systems would deliver functional enzymes to their 
native action sites, namely the endocytic compartments of diseased cells.
EVs are cell-derived nano-vesicles that play an important role in mediating cell-to-cell communication21–23. 
These vesicles have been shown to shuttle a large number of macromolecules, including proteins, enzymes, 
nucleic acid and lipids to various tissues and organs24,25. Due to their intrinsic tissue-penetrating ability, EVs 
represent a more desirable delivery tool over other existing technologies such as liposomes, synthetic polymers 
and gold nanoparticles26,27. In fact, engineered EVs, particularly exosomes (the subpopulation of EVs derived 
from multiple vesicular bodies), have been shown to deliver RNA therapeutics or other drugs to both brain 
tissues and deep-seated cancer cells28–31. Recently, we have developed a decoy exosome system that functions as 
a biological sponge to antagonize tumor-necrosis factor alpha32. In this previous study, we tested the hypothesis 
that engineered EVs or exosomes and related biologics can function as an effective extracellular sponge binding 
to inflammatory agents in the extracellular space. In exploiting EVs for targeted delivery of bioactive enzymes 
to an intracellular site for the treatment of human diseases33, one abstract reported the preliminary work on 
the potential use of opto-genetically engineered exosomes and β-glucocerebrosidase (GBA) for the treatment of 
Gaucher disease34
Human β-glucocerebrosidase (GBA) is an important well-characterized lysosomal enzyme that localizes 
within the endocytic compartment of human cells. Defective forms of GBA are responsible for Gaucher dis-
ease and previous studies have shown that the introduction of functional GBA can effectively reverse disease 
symptoms35,36.
Here, we describe a de novo method to load GBA onto exosomes by developing a genetic fusion protein using 
an exosome targeting transmembrane protein, VSVG. These GBA-loaded exosomes can be isolated in a pure form 
from conditioned medium. The isolated exosomes/EVs are added to the medium of targeted recipient cells, where 
they effectively deliver bioactive GBA to their endocytic compartments.
Methods
Materials. Reagents were obtained from the following commercial sources: recombinant human glucosylce-
ramidase/GBA protein (R&D Systems/Bio-Techne; Minneapolis MN); 4-methylumbelliferyl-beta-D-glucopyra-
noside, sodium cholate, glycine, citric acid, DTT, and NaOH (Sigma Aldrich; St. Louis, MO); Human embryonic 
kidney cell line HEK293 (Alstem; Richmond, CA); Human glioblastoma cell line U87 (ATCC; Manassas, VA); 
Human hepatocellular carcinoma cells, HepG2 (ATCC; Manassas, VA); Lipofectamine2000 (Thermo Fisher 
Scientific; Waltham, MA); FuGENE6 (Promega; Madison, WI); Dulbecco’s Modified Eagle Medium (DMEM), 
fetal bovine serum (FBS), UltraCULTURE (Lonza; Allgendale, NJ); LysoTracker Red DND-99, CellLight Early 
Endosomes-RFP/Late Endosome-RFP BacMam 2.0, polyclonal TurboGFP primary antibody, goat anti-rabbit 
horseradish peroxidase conjugated secondary antibody (Invitrogen; Carlsbad, CA); Dot-blot antibody arrays, 
ExoQuick-TC exosome precipitation solution (SBI; Palo Alto, CA); Prestained protein markers and precast 
4~12% SDS-PAGE (GenScript; Piscataway, NJ); Hoechst 33342 and Pierce ECL Western Blotting Substrate 
(ThermoFisher Scientific; Fremont, CA).
Vector design and construction. The mammalian vector expressing the VSVG-GFP fusion gene was con-
structed as previously described [28]. The full-length coding sequence of human GBA (XM_006711270) was 
purchased from Genscript (Piscataway, NJ). The partial GBA coding sequence was inserted into two locations of 
the VSVG-GFP vector, yielding two construct designs, GBA-VSVG-GFP and VSVG-GFP-GBA, depending on 
whether GBA were appended at the N- or C- terminus of the VSVG-GFP vector respectively. The final constructs 
were verified by double-stranded DNA sequencing (GenScript; Piscataway, NJ); their encoded chimeric proteins 
were annotated and provided (Supplementary Sequences).
cell culture and transfection. Human cells (HEK293, U87 and HepG2) were cultured in high glucose 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS, 2 mM glutamine and 100 U/mL pen-
icillin/streptomycin (Gibco; Manassas, VA). Cells were maintained at 37 °C and 5% CO2. Cells were transiently 
transfected using either Lipofectamine 2000 transfection reagents. Typically, 1.5~2 μg of plasmid DNA was used 
to transfect cells (40~60% confluency) in each well of a 6-well plate. After 24~48 hours, over 80% of cells were 
effectively transfected.
nuclear and lysosomal staining. Cultured cells on glass bottom dishes were incubated with a PBS-diluted 
Hoechst 33352 stain (1:1000 dilution) for 10 minutes at 37 °C. The Hoechst solution was removed and cells were 
washed with PBS before imaging via confocal microscopy to show nuclear staining (blue). Similarly, cells were 
stained with a dilution of 75 nM LysoTracker Red DNA-99 in cultured medium and incubated at 37 °C for 30 min-
utes. The LysoTracker solution was then replaced with either fresh culture medium or PBS before imaging via 
confocal microscopy to show lysosomal staining (red).
extracellular vesicle preparation. A combination of centrifugation, ultrafiltration and precipitation was 
used to prepare EVs/exosomes as described37. Briefly, HEK293 cells cultured in 10% FBS supplemented com-
plete medium were switched to serum-free UltraCULTURE for 48 hours. The conditioned medium was then col-
lected, centrifuged at 1500xg for 10 min and filtered through a 0.2 µm syringe filter to remove cell debris and large 
extracellular vesicles ( > 200 nm in diameter). Finally, EV-containing medium was mixed with the ExoQuick-TC 
solution (1:4 dilutions) and incubated overnight at 4 °C. The precipitate was then collected by centrifugation at 
3,000xg for 90 min at 4 °C. The EV pellet was resuspended in PBS and stored at −20 °C.
nanoparticle tracking analysis (ntA). EVs isolated from modified producer cells were subjected to nan-
oparticle tracking analysis (NTA) using a NanoSight LM10 instrument (Malvern Instruments Ltd; Malven, UK) 
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with a 405 nm and 60 mV laser source as previously described [31]. Typically, 1 ml of a diluted exosome prepara-
tion was used for the laser light scattering study. The instrument rendered 3 recordings per sample at 60 seconds 
each; NTA software was then used to determine the size distribution of exosomes.
Western blot and dot-blot analysis. Whole cell lysates (WCLs) were prepared from either control or 
transiently transfected HEK293 cells38. 30–150 μg of proteins from either exosome or WCLs were loaded on a 
precast gradient gel (4~12%) and blotted on a polyvinylidenedifluoride membrane. The membrane was blocked 
for 1 hour at room temperature before overnight incubation at 4 °C with anti-rabbit Turbo-GFP antibody (1:2000) 
and subsequently with horseradish peroxidase conjugated goat anti-rabbit secondary antibody (1:4000) for 1 hour 
at room temperature. The membrane was visualized with Pierce ECL Western Blotting Substrate on ImageQuant 
LAS 500 imager (GE Healthcare Life Sciences; Issaquah, WA).
A dot-blot kit from SBI (Palo Alto, CA) was used to identify target proteins as described39,40. Each blot con-
tained 12 pre-printed spots and featured 8 antibodies against exosomal markers including CD63, CD81, ALIX, 
FLOT1, ICAM1, EpCam, ANXAS and TSG101, as well as a negative control, cytosolic GM130 to identify any cel-
lular contamination. 100~200 μg of exosomal proteins were used in each assay according to the immuno-binding 
and detection protocol described in the user manual.
enzyme assays. GBA activity was determined fluorometrically using 4-methy-lumbelliferyl-beta- 
D-glucopyranodide (NBD-Glu) as a substrate40,41. For each assay, the NBD-Glu solution was freshly prepared and 
positive controls (recombinant human GBA) was included. Typically, the enzymatic reaction was carried out in 
a volume of 50 µl, using either 150 µg (WCLs) or 50 µg (exosomes), in a pH 6 solution containing 50 mM sodium 
citrate, 25 mM sodium cholate and 5 mM DTT. The reaction was incubated for 30 min at 37 °C and stopped by 
adding 50 µl of stop solution (0.5 M glycine, 0.3 NaOH, pH 10). The fluorescent signal at a wavelength of 365 nm 
excitation and 445 nm emission was recorded using a TECAN infinite M200PRO plate reader.
fluorescence-activated cell sorting (fAcS) analysis. Equal amounts of exosomes were chemically 
stained using a green fluorescent dye, Exo-Glow (SBI, Palo Alto, CA) according to the manufacturer’s instruc-
tions. 0.3 µg/μl of stained exosomes were added into cultured media of HEK293 cells to allow for cellular uptake 
during 48 hour incubation periods. The cells were then washed, trypsinized and re-washed using PBS. The corre-
sponding cells were then subjected to FACS analysis using channels to detect GFP fluorescence42.
fluorescence and confocal microscopy. For live cell experiments, cultured cells were imaged using an 
Olympus fluorescence microscope (Waltham, MA), or a Leica TCS SP8 confocal microscope (Buffalo Grove, IL). 
Images were taken at indicated time-points using the same exposure conditions within the group for comparison. 
To show the intracellular localization of the fluorescent fusion proteins, both fluorescence and phase/TLD images 
were overlaid using the Leica Las X imaging software.
Data collection, analysis and statistics. The student’s t-test was used to determine statistical significance 
of our studies, with P values < 0.05 being considered significant. All values were expressed as mean ± standard 
deviation.
Results
System design and exosome loading strategy of lysosomal enzyme GBA. We have previously 
developed a method that enables protein loading onto exosomal targeting and anchoring protein, VSVG42. Using 
a genetic fusion approach, it is possible to utilize intracellular targeting and anchoring of a protein payload to 
the exosomal compartments of human cells. In this study, this approach was used to load the lysosomal enzyme 
GBA onto exosomes by fusing GBA with VSVG-GFP (Fig. 1a). The coding sequence of mature human GBA 
was inserted in one of two locations, creating two distinct fusion genes, whose expression was controlled by a 
CMV promoter (Fig. 1a). To ensure fusion proteins were anchored to the exosomal membrane with the correct 
spatial topography, we left the signal peptide (SP) sequence and the transmembrane helix of VSVG fully intact 
in all constructs. The first fusion gene (Upper, Fig. 1a) was expected to produce a protein chimera with GBA at 
the N-terminus of the VSVG-GFP, while the second (Lower, Fig. 1a) should create a chimera with GBA at the 
C-terminus after the GFP. When incorporated in exosomes, the first chimera should display the GBA enzyme on 
the outer surface of exosome, while in the second chimera, GBA would localize within the lumen of the exosomes 
(Fig. 1b). We fused a fluorescent GFP to all constructs, which allowed us to observe and quantify molecular 
trafficking of the gene product in human cell cultures. Compared to earlier studies on exosome-engineering, we 
can identify several innovations: the loading of functional GBA enzymes with defined geometry on the exosome 
surface and the integration of a sensitive probe for high-resolution imaging of distributions of the engineered 
exosomes in live cells28,42,43.
Loading bioactive GBA onto exosomes in living human cells. First, we investigated the subcellular 
localization of GBA fused to the VSVG scaffold and imaged the GFP to visualize its intracellular trafficking to 
exosomes in live HEK293 cells. The cells were transfected with genetic constructs as detailed in the Methods 
section and imaged via confocal fluorescence microscopy for up to 3 days to assess GFP expression patterns and 
intracellular localization. Analysis of these images showed that within 24-hours of post-transfection with the 
GBA-VSVG-GFP construct, GFP fusion proteins (green, arrow) localized to puncta (Fig. 2,a1). The cytosolic 
localization of these intracellular fluorescent proteins was evident in an overlay of fluorescence and phase contrast 
images (Fig. 2,a4). This finding was consistent with the localization of the fusion protein to endocytic structures. 
Similar results were obtained when cells were transfected with VSVG-GFP-GBA (Fig. 2,a13–16). Together these 
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data indicated that the protein chimeras including the GBA appendages were efficiently expressed and properly 
directed to exosomes in transfected cells.
We next investigated whether these displayed fluorescent VSVG fusion proteins were correctly integrated into 
pre-exosomal compartments during biogenesis. For this purpose, HEK293 cells were co-transfected with one of 
the GBA-VSVG-GFP constructs and one of two validated exosomal markers, namely CD63-RFP or XPACK-RFP. 
Confocal images of transfected cells were recorded for 72 hours after co-transfection. The results revealed exten-
sive overlap of green and red fluorescence signals of GBA-VSVG-GFP co-transfected with either CD63-RFP 
(Fig. 2b5–8) or XPACK-RFP (Fig. 2c9–12). We obtained similar results in cells expressing VSVG-GFP-GBA and 
either CD63-RFP (Fig. 2e17–20) or XPACK-RFP (Fig. 2f21–24). Together, our data strongly indicate that both 
GBA protein chimeras successfully targeted and incorporated themselves onto exosomes before their release to 
extracellular environments.
Post-translational modification of GBA such as glycosylation is an important step in the production of a 
functional enzyme44,45.To assess whether our expressed enzymes were active post-exosomal loading, transfected 
cells were cultured in serum free media and modified exosome were isolated as described. GBA activity was then 
measured from isolated exosomes. Whole cell lysates (WCL) were prepared from the transfected cells as detailed 
in the Methods section. As shown in Fig. 3b, the relative GBA activities in the WCL drastically increased by 7.1- 
and 8.4-fold for GBA-VSVG-GFP and VSVG-GFP-GBA respectively, compared to a mock control (P < 0.001). 
As expected, the GBA activities in isolated exosomes also increased by 4.0- and 4.2-fold compared to those mock 
controls for GBA-VSVG-GFP and VSVG-GFP-GBA respectively (Fig. 3c, P < 0.001).
In summary, our data support that VSVG serves as a molecular scaffold that can both target and load their 
appended GBA and GFP components to exosomes in HEK293 cells. The readily detectable GFP signal in trans-
fected cells suggests that the loading of both GBA and GFP is robust. Moreover, the drastically increased levels of 
GBA activity demonstrate that the enzyme payloads in both transfected producer cells and modified exosomes 
remain active.
characterization of engineered eVs. We next characterized isolated EVs to assess whether the 
gene-product modifications affected their physical or biochemical properties. HEK293 cells were cultured and 
transfected with either construct for 72 hours, before WCL and EVs preparation as described earlier. First, we 
verified the size and particle distribution of the modified EVs were consistent with those of native (control) EVs, 
using a NanoSight NS80 system. As shown in Fig. 4, the peak size of 62–64 nm of exosomes modified by either 
GBA-VSVG-GFP (middle panel) or VSVG-GFP-GBA (right panel) did not differ from that measured in native 
(control) EVs (left panel).
To further confirm that the purified product consisted of exosomes rather than other EVs, we performed 
an immune dot-blot analysis on isolated exosomes using a panel of 9 anti-exosomal antibodies following the 
manufacturer’s protocol. The blot revealed positive stains for 7 out of 8 exosome markers including FLOT1, 
Figure 1. Design of GBA fusion proteins for exosome targeting and anchoring. (a) Schematic illustration of 
expression cassettes for two GBA fusion genes. CMV: cytomegalovirus promoter; SP: signal peptide coding 
sequences, where the red arrows indicate the cleavage site of the SP; PolyA: polyadenylation signaling. (b) GBA-
loaded exosome illustration. The red arrow heads indicate different localization of GBA enzymes on exosomes 
according to the topology of VSVG on the lipid bilayer. The mature GBA is situated on the outer surface 
of exosome when GBA is fused at the N-terminus of VSVG, while GBA is situated within the lumen of the 
exosome when tagged at the C-terminus of VSVG.
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ICAM1, CD81, CD63, EpCam, ANX5, and TSG101 for GBA-VSVG-GFP modified exosomes (Fig. 4b, Upper 
Panel) as well as native (control) (Fig. 4b, Lower Panel). The control cytosolic marker (GM130) was negative on 
both dot-blots, an indication of high purity of our exosome preparations. The same dot-blot but with different 
exposure times (Fig. S1) can be found in the Supplementary Information.
Next, we investigated whether our isolated EVs, exosomes, were properly loaded with the genetically encoded 
chimeric proteins. As shown in Fig. 4c, confocal fluorescence images of purified exosomes presented strong GFP 
expression for both GBA-VSVG-GFP and VSVG-GFP-GBA modified exosomes, indicating that the chimeras 
were appropriately targeted and anchored to exosomes. To further demonstrate that the full-length chimeras 
were properly expressed in transfected cells and integrated into secreted exosomes, we performed Western-blot 
analysis on both WCL and modified exosomes. Using an anti-TurboGFP antibody, we identified a ~140 kDa band 
was apparent in both GBA-VSVG-GFP and VSVG-GFP-GBA transfected cells but not in mock control samples 
(Fig. 4d), suggesting specific expression of the full-length chimeras in isolated exosomes and transfected pro-
ducer cells. An uncropped immune-blot (Fig. S2) can be found in the Supplementary Information. Additionally, 
we notice some smaller positive bands (such as ~113 kDa) in both WCL and exosome samples, which may have 
resulted from differential post-translational modifications or partial degradations during sample preparation or 
exosome loading.
Together, these data demonstrate that our chimeras were properly expressed and integrated into EVs, most 
likely exosomes. These exosomes were then were released into conditioned medium and isolated with other EVs, 
after which they still retained their activity.
Targeted delivery of GBA to the endocytic compartment of recipient cells. Next, we investi-
gated the intracellular delivery of GBA via engineered exosomes to human recipient cells using a combination of 
Figure 2. Molecular trafficking of GBA-fusion proteins in genetically modified HEK293 cells. HEK293 cells 
were transfected with either GBA-VSVG-GFP alone (a) or co-transfected with either endosomal marker CD63-
RFP (b) or XPACK-RFP (c) for 72 hours. Confocal images of live cells expressing GBA-VSVG-GFP (a1; green, 
arrow) and with Hoechst nuclear stain (a2, blue) and their overlay (a4) are shown. GBA-VSVG-GFP (green; 
b5, c9) is co-expressed with either CD63-RFP (b6) or XPACK-RFP (c10) as shown by their co-localization 
in overlay images (b8, c12). Parallel experiments were performed using VSVG-GFP-GBA, and similar results 
were obtained showing the expression of VSVG-GFP-GBA (d13–16) and co-expression with either CD63-RFP 
(e17–20) or XPACK-RFP (f21–24). Scale bar represents 10 µm. Arrows indicate subcellular locations of fusion 
protein. Nu: nucleus.
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confocal monitoring and enzymatic assays. We first performed confocal imaging on HEK293 cells to track the 
distributions of these GBA chimeras after internalization. We observed cellular uptake in a concentration and 
time-dependent manner. The uptake was initially noticeable after 3~6 hours and became attenuated and plateaued 
after 24 hours (Levy D et al. unpublished data). Exosomes were presumed to enter cells via receptor-mediated 
endocytosis through surface protein interactions (Fig. 5a)46. Because VSVG ligand binds strongly to the 
VLDL-receptor, which appears on the surface of all human cell types, it was expected that VSVG-modified 
exosomes could effectively enter recipient cells, ultimately targeting their endocytic compartments46. In the case 
of GBA-VSVG-GFP modified exosomes, GBA enzymes would situate on the outer surface of exosomes, thus 
allowing for degradation of their substrates within the endosomal lumen. We further hypothesized that in the 
case of VSVG-GFP-GBA, the enclosed GBA enzyme would be released after the integration of modified exosomes 
into late endosomes (Fig. 5a). To determine the subcellular locations of modified exosomes post-uptake by recip-
ient cells, we first added the either GBA-VSVG-GFP or VSVG-GFP-GBA loaded exosomes into the culture 
medium of HEK293 cells. We monitored the cellular up-take processes up to 72 hours using fluorescence micros-
copy. The punctated GFP-fluorescence signal within recipient cells was visible as early as 6 hours after uptake, 
with increasing intensity for 48 hours and persisted at least72 hours. Confocal images of cellular uptake of mod-
ified GBA-VSVG-GFP (Fig. 5,b1–4) and VSVG-GFP-GBA (Fig. 5,b5–8) endosomes recorded at 48 hours clearly 
identified punctated distributions of fluorescent label in the cytosol, which would be consistent with endocytic 
compartmentalization post-uptake. This cellular uptake was also observed in two additional human cell types, 
including human glioblastoma cell line U87 (Fig. S3a in Supplementary Information) and human hepatoma cell 
line HepG2 (Fig. S3b in Supplementary Information). To further verify whether these puncta were truly endo-
cytic components, we carried out a co-localization assay using known markers for either early endosome, late 
endosomes or lysosomes. We identified endosomes by transfecting HEK293 cells with either early (RAB5a-RFP) 
or late endosome (RAB7a-RFP) markers before adding GBA-VSVG-GFP loaded exosomes into culture medium 
for cellular uptake. Confocal images revealed significant co-localization (yellow) of uptake exosomes (green) 
with red endosomal markers of early endosomes (Fig. 5c1–5) and late endosomes (Fig. 5c6–10). In a separate 
study, we first added GBA-VSVG-GFP loaded exosomes (green) to HEK293 cells to allow for cellular uptake for 
24 hours before staining the cells with LysoTracker Red DND-99 to indicate lysosomal compartments. Analysis 
Figure 3. Enzyme assay protocol and GBA activities in whole cell lysates and exosomes. (a)Workflow of 
preparation of whole cell extracts and exosomes for a GBA enzyme assay following transfection of HEK293 cells 
with either GBA-VSVG-GFP, VSVG-GFP-GBA, or control (unmodified plasmid) for 24 hours. At the end of 
transfection, cells were collected and both the whole cell lysates and exosomes were prepared for a GBA enzyme 
assay. The relative GBA activity in whole cell extracts (b) and in exosomes (c) is shown. All values are expressed 
as mean ± standard deviation (n = 3). ***p < 0.001 significant vs control, using a student-t test.
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of these images showed that the engineered exosomes colocalized with lysosomal marker probe (Fig. 5c11–15). 
This finding supports our view that the internalized exosomes ultimately migrate to lysosomes. Together, these 
results demonstrate that our genetically modified exosomes were able to target endocytic compartments after 
entering recipient cells.
Next, we quantified the effectiveness of engineered exosomes to enter recipient cells by using FACS analy-
sis. Following transfection of the cells with our engineered chimeras, we isolated exosomes expressing either 
the GBA-VSVG-GFP or VSVG-GFP-GBA and further labeled these preparations with a green fluorescent dye 
to enhance the sensitivity of FACS detection. We introduced the fluorescent dye-labeled exosomes to cultured 
HEK293 cells for 48 hours and conducted FACS to evaluate exosome uptake. When compared to unlabeled con-
trol exosomes, the uptake rates of both GBA-VSVG-GFP and VSVG-GFP-GBA were similar and equal to the con-
trol values of 73~75%. Overall, the uptake into HEK293 cells showed a 50-fold increase in fluorescent intensity 
over the unlabeled control (Fig. 6a). Thus, FACS data independently confirmed that our GBA-loaded exosomes 
are effective in gaining entry to recipient cells.
Next, we tested whether GBA remained enzymatically active after internalization in recipient cells. We con-
ducted an enzyme assay to quantify the levels of GBA activity in engineered exosomes post-cellular uptake and 
compared these results to an unmodified control group. Equal amounts of GBA-VSVG-GFP, VSVG-GFP-GBA 
and unmodified control exosomes were added to HEK293 cells for 48 hours. Subsequently, GBA activities from 
the WCL and the resultant activities normalized to the control group (set as 100%). As shown in Fig. 6b, both the 
GBA-VSVG-GFP and VSVG-GFP-GBA modified exosomes exerted significantly greater GBA activity by ~45% 
(P < 0.05) and ~40% (P < 0.01) respectively, compared to the unmodified control. Thus, our data indicate that the 
genetically modified exosomes taken up by recipient cells display functionally active GBA.
Figure 4. Characterization of engineered exosomes. HEK293 cells were transfected with either GBA-VSVG-
GFP, or VSVG-GFP-GBA, or mock control (control plasmid) for 72 hours, and exosomes were prepared 
and subjected to nanoparticle-tracking analysis (a), a dot-blot array analysis (b), confocal images (c) and 
Western blot analysis. (d) As shown in (a), there is no difference of particle size and distribution between these 
exosomes from control cells a GBA-VSVG-GFP or VSVG-GFP-GBA transfected cells. Dot-blot array analysis 
of 9 exosomal markers also showed similar expression pattern of engineered exosomes from cells transfected 
with GBA-VSVG-GFP (b; upper panel) vs. non-modified control (b; lower panel). (c) Confocal images of 
GBA-VSVG-GFP and VSVG-GFP-GBA modified exosomes. Western blot analysis showed the expression 
of GBA-VSVG-GFP and VSVG-GFP-GBA fusion proteins in transfected cell lysates or exosomes, compared 
with background levels of that in a mock control. (d) Arrows indicates the predicted size of the trimeric 
(GBA + VSVG + GFP) fusions (~140 kDa), and possibly differently post-translational modification or partially 
de-gradated bands (~113 kDa).
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In summary, the methods we have described to load GBA on the outer surface and inner lumen of exosomes 
produces functional enzymes that are properly directed to endocytic compartments within recipient cells. The 
highly efficient delivery and internalization of our modified exosomes was shown to significantly enhance GBA 
activity within these cells.
Discussion
We have developed a genetic method to produce engineered exosomes that deliver functional lysosomal enzymes 
to the endocytic compartments of recipient cells. Unlike other nanoparticle-based carriers, exosomes are pro-
duced in human cells and exhibit intrinsic and specific mechanisms to enter the cytosol of living cells both in vitro 
and in vivo. Consequently, engineered exosomes hold promise in delivering protein payloads to targeted cells that 
are deep-seated in brain tissue28. Using this method, we effectively demonstrated that our engineered exosomes 
successfully delivered GBA, an enzyme associated with LSD, to human cells, where they target endocytic com-
partments. Our method may provide an alternative and more effective treatment option to manage LSDs, the 
largest family of human metabolic diseases. That includes Gaucher disease, which has been linked to neurological 
complications.
Over the past decade, there have been significant advances in engineering exosomes as drug delivery vehicles. 
The ability to use exosomes to deliver therapeutic cargo, including siRNA, mRNA, proteins, and small mole-
cule drugs presents new opportunities for targeted delivery to treat various human diseases including cancer, 
inflammation, and hereditary diseases such as LSDs47–51. While loading and delivery of biologically active lys-
osomal enzymes onto exosomes has been hypothesized, we are unaware of any demonstration of the feasibil-
ity or effectiveness of this approach. Lysosomal enzymes have a natural address (targeting lysosomes instead 
of exosomes). Moreover the activities of lysosomal enzymes require specific post-translational modifications, 
including glycosylation44,45. Consequently, the delivery of these enzymes to cell models of LSDs requires the 
development of a robust exosome-targeting scaffold that projects the enzyme with the correct geometry and 
allows for post-translational modifications during exosome biogenesis. To achieve this goal, we employed the 
single transmembrane protein, VSVG, which we have previously shown to be efficiently expressed in human 
cells. VSVG serves as a scaffold amenable to load proteins onto exosomes in a predefined manner by genetic 
fusion42. VSVG has a number of advantages for exosome targeting compared to other exosome-targeting scaf-
folds, including tetraspanins (CD9, CD63, and CD81), lipid anchoring peptide (C1C2 domain of lactacherin) 
and lysosome membrane protein (Lamp2B)37,43,51,52. First, VSVG integrates into exosomal membranes providing 
Figure 5. Delivery of GBA enzyme into endocytic compartments of recipient cells. (a) Schematic illustration 
of cellular uptake and lysosomal release of engineered GBA via the endocytosis process. (b) Parental HEK293 
cells were treated with either GBA-VSVG-GFP (b1–4) or VSVG-GFP-GBA (b5–8) loaded exosomes in a glass 
bottom culture dish. 48 hours post-treatment, fluorescent, Hoechst stained, and PMT-Trans images were 
taken and overlaid (b1 and b8). In a set of separate experiments, GBA-VSVG-GFP or VSVG-GFP-GBA loaded 
exosomes were used to treat HEK293 cells that were either transfected with RFP-labeled early/late endosome 
reporters, Rab5a-RFP and Rab7a-RFP (c1–10) or stained with a red fluorescent-dye specific to lysosomes  
(c11–15). Arrows indicate early/late endosomes, or lysosomal structures. Scale bar 10 μm.
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a stable anchoring mechanism for their fused-enzyme cargo. Thus, VSVG is not conceptually different from 
lysosome proteins and lipid anchors, neither of which is sufficiently stable nor can they be specifically targeted. 
Second, VSVG is a single transmembrane protein with a well-defined domain structure and membrane topology, 
composed of an ectodomain, a transmembrane helix, and a small luminal peptide42. This linear structure stream-
lines the design of geometrically-defined fusion proteins that may be directed to the outer surface or inside the 
lumen of the exosome. We note other scaffolds often lack this flexibility. For example, tetraspanins and C1C2 
restrict their cargo loading to either the inside or the outside of the exosomal membrane37,52, while Lamp2B 
requires additional glycosylation to maintain the stability of its protein cargo53. Third, VSVG has a programmable 
ectodomain that can be easily swapped with cell-specific peptides or nanobodies, therefore permitting advanced 
engineering for additional benefits such as specific cell type targeting, or purification42.
Post-translational modification of GBA such as glycosylation is an important step in the production of a 
functional enzyme44,45. Glycosylation occurs co-translationally and is needed for the stability and lysosomal tar-
geting, therefore endogenous activities in lysosomes41,54–56. However, our engineered GBA-fusion proteins still go 
through normal translation, the intrinsic enzyme activities may not be severely affected as evidenced by readily 
detected increased GBA activities in our transfected cells and EVs. It remains unknown if our GBA-fusion pro-
teins are subjected to differentially co-translational glycosylations as compared to native GBA.
Another unique feature of this study is the genetic design used to produce modified exosomes. The exosomes 
present functional GBA enzymes in two different spatial conformations (either the outer or inner surface of 
exosome membrane), and the scaffold is capable of accommodating a reporter protein (GFP). GFP is espe-
cially useful in the observation of intracellular trafficking and uptake of purified exosomes in recipient cells. 
Interestingly, the two different placements of GBA enzyme lead to similar results. However, the two methods may 
have distinct advantages and potential limitations. The surface display approach may allow to load many copies 
of the enzyme to the exosome membrane surface, which may also increase the chance of enzymatic degradation 
during delivery. Placing enzymes within the lumen of the exosome could provide increased protection and poten-
tially elicit fewer off-target interactions, as the therapeutic enzyme would not be able to interact with external 
molecules, including proteases. Nevertheless, we did not observe a significant difference between these two GBA 
configurations, suggesting both approaches are effective. Further confirmation of GBA-loaded EVs using either 
patients-derived GBA mutant fibroblast cells or in vitro GBA mutant cells as functional relevance is critical for 
further development. Additionally, studies using animal models are needed to determine which composition 
would result in the most effective therapeutic benefit.
Figure 6. Intracellular delivery of bioactive GBA into living HEK293 cells. (a) Parental HEK293 cells were 
treated with either GBA-VSVG-GFP or VSVG-GFP-GBA modified exosomes for 48 hours before being 
subjected to FACS analysis. Right shifts in fluorescent signals for both GBA-VSVG-GFP (red line) and VSVG-
GFP-GBA (green line) were observed as compared to control cells treated with unlabeled exosomes (black 
line). (b) HEK293 cells were treated with either isolated engineered exosomes or unmodified control exosomes 
for 48 hours, then washed and lysed. Equal amounts of proteins from the whole cell extracts were subjected to 
GBA enzymatic assays as described in the Materials and Methods. Values were expressed as mean ± standard 
deviation from 3 independent experiments (n = 11). *p < 0.05, **p < 0.01 significant vs control using a 
student-t test.
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While our exosome surface display is promising for treating Gaucher disease, there may be some in vivo 
limitations such as immunological responses to this biologics, which needs further studies using animal models.
conclusion
We have developed a genetic approach to produce enzyme-loaded EVs/exosomes for the targeted delivery of GBA 
enzyme to human cells. Through fusion with VSVG, the enzyme payloads are strongly enriched in EVs/exosomes, 
which are delivered to the endocytic compartments (early/late endosomes and lysosomes) of recipient cells. Our 
proof-of-concept work establishes the engineering methodology of EVs/exosomes for targeted delivery of bio-
active lysosomal enzymes for a potential treatment strategy of Gaucher disease, especially for those with severe 
forms of the disease associated with neurological complications.
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